Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 5, 2026, 4:11 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 691 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Primary Headache Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

Single-Ascending Dose Study of AMG 333 in Healthy Subjects and Subjects With Migraines

NCT01953341
View directory record Official record
Conditions
Migraine
Interventions
AMG 333, Placebo
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 55 Years
Enrollment
74 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Dec 9, 2014 · Synced Oct 5, 2026, 4:11 AM EDT
Completed Phase 1 Interventional

Psilocybin for the Treatment of Cluster Headache

NCT02981173
View directory record Official record
Conditions
Cluster Headache
Interventions
0.143 mg/kg Psilocybin or 10 mg Psilocybin, 0.0143 mg/kg Psilocybin or 1 mg Psilocybin, Placebo
Drug
Lead sponsor
Yale University
Other
Eligibility
21 Years to 65 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
1
States / cities
West Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Dec 15, 2023 · Synced Oct 5, 2026, 4:11 AM EDT
Completed Phase 2 Interventional

Safety and Efficacy Trial of MTX101 2mg for the Acute Treatment of Migraine in Adults

NCT06728553
View directory record Official record
Conditions
Migraine
Interventions
MTX101, Placebo
Drug
Lead sponsor
Manistee Therapeutics
Industry
Eligibility
18 Years to 65 Years
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
7
States / cities
La Jolla, California • Santa Monica, California • Miami, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 7, 2025 · Synced Oct 5, 2026, 4:11 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Acute Treatment Trial in Adult Subjects With Migraines

NCT03872453
View directory record Official record
Conditions
Migraine
Interventions
Zavegepant, Zavegepant matching placebo, Intranasal Aptar Pharma Unit Dose System
Drug · Device
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
2,154 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
82
States / cities
Mobile, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 75 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2023 · Synced Oct 5, 2026, 4:11 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Osteopathic Manipulative Treatment and Migraine Headaches

NCT04976985
View directory record Official record
Conditions
Chronic Migraine, Migraine Disorders, Headache Disorders, Headache, Migraine
Interventions
Osteopathic Manipulative Therapy (OMT), Standard of care
Procedure · Other
Lead sponsor
St. Luke's Hospital, Pennsylvania
Other
Eligibility
18 Years to 50 Years
Enrollment
140 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2022
U.S. locations
1
States / cities
Bethlehem, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 3, 2021 · Synced Oct 5, 2026, 4:11 AM EDT
Terminated Phase 2 Interventional

Paracervical Injection for Headache in the Emergency Department

NCT04109885
View directory record Official record
Conditions
Headache Disorders, Primary, Pain Management, Emergency Department
Interventions
Paracervical injection, prochlorperazine and diphenhydramine.(Standard Treatment)
Drug
Lead sponsor
Christian Fromm, MD
Other
Eligibility
18 Years to 64 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 1, 2024 · Synced Oct 5, 2026, 4:11 AM EDT
Completed Phase 4 Interventional Results available

Comparison of Ketorolac Nasal Spray to Sumatriptan Nasal Spray and Placebo for Acute Treatment of Migraine

NCT01807234
View directory record Official record
Conditions
Migraines
Interventions
Ketorolac, Sumatriptan, Placebo
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 65 Years
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 13, 2017 · Synced Oct 5, 2026, 4:11 AM EDT
Completed Phase 3 Interventional Results available

A Study of LY2951742 (Galcanezumab) in Participants With Cluster Headache

NCT02797951
View directory record Official record
Conditions
Episodic Cluster Headache, Chronic Cluster Headache
Interventions
Galcanezumab
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
165 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
11
States / cities
Phoenix, Arizona • Palo Alto, California • Santa Monica, California + 8 more
Source: ClinicalTrials.gov public record
Updated Feb 10, 2022 · Synced Oct 5, 2026, 4:11 AM EDT
Completed Phase 2 Interventional Results available

A Phase IIb, Randomized, Double-Blind, Placebo-Controlled Study of Elismetrep (K-304) in the Treatment of Migraine

NCT06848075
View directory record Official record
Conditions
Migraine
Interventions
Elismetrep (K-304) 2 mg, Elismetrep (K-304) 5 mg, Elismetrep (K-304) 10 mg, Elismetrep (K-304) 20 mg, Placebo
Drug
Lead sponsor
Kallyope Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
431 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
66
States / cities
Birmingham, Alabama • Mobile, Alabama • Tucson, Arizona + 61 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 5, 2026, 4:11 AM EDT
Recruiting No phase listed Observational

Puberty, Testosterone, and Brain Development

NCT06670053
View directory record Official record
Conditions
Gender Identity, Gender Dysphoria in Adolescents and Adults, Headache, Transgender
Interventions
Testosterone
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
12 Years to 20 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Oct 5, 2026, 4:11 AM EDT
Completed Not applicable Interventional

A Nutritional Intervention for Migraines

NCT01547494
View directory record Official record
Conditions
Migraines
Interventions
Vegan Diet, mixture of omega3 and vitamins
Other · Dietary Supplement
Lead sponsor
Physicians Committee for Responsible Medicine
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated May 14, 2013 · Synced Oct 5, 2026, 4:11 AM EDT
Completed No phase listed Observational

Correlation of Calcitonin Gene-Related Peptide (CGRP) Levels in Saliva With the Evolution of an Attack of Migraine

NCT00772473
View directory record Official record
Conditions
Headache, Migraine
Interventions
subjects personal triptan
Other
Lead sponsor
Clinvest
Other
Eligibility
18 Years to 65 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Springfield, Missouri
Source: ClinicalTrials.gov public record
Updated May 25, 2009 · Synced Oct 5, 2026, 4:11 AM EDT
Completed Phase 3 Interventional Results available

A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate STS101 in the Acute Treatment of Migraine

NCT03901482
View directory record Official record
Conditions
Migraine, Migraine With Aura, Migraine Without Aura
Interventions
Dihydroergotamine, Placebos
Drug
Lead sponsor
Satsuma Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
1,201 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
117
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 96 more
Source: ClinicalTrials.gov public record
Updated Jun 29, 2023 · Synced Oct 5, 2026, 4:11 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Pharmacokinetic Study of an Experimental Paracetamol Formulation

NCT01476176
View directory record Official record
Conditions
Headache, Tension-Type
Interventions
Experimental paracetamol, Paracetamol marketed formulation
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 55 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Nov 24, 2014 · Synced Oct 5, 2026, 4:11 AM EDT
Recruiting No phase listed Observational

Observational Study to Assess Maternal, Fetal and Infant Outcomes Following Exposure to Rimegepant

NCT05046613
View directory record Official record
Conditions
Migraine
Interventions
Rimegepant, Not taking Rimegepant
Other
Lead sponsor
Pfizer
Industry
Eligibility
0 Years and older · Female only
Enrollment
780 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2034
U.S. locations
1
States / cities
Wilmington, North Carolina
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Oct 5, 2026, 4:11 AM EDT
Completed Phase 4 Interventional Results available

Drug and Non-Drug Treatment Of Severe Migraine

NCT00910689
View directory record Official record
Conditions
Migraine Headache
Interventions
Propranolol or nadolol, Placebo control, Behavioral Migraine Management (BMM), Optimal Acute Therapy
Drug · Behavioral
Lead sponsor
Ohio University
Other
Eligibility
18 Years to 65 Years
Enrollment
232 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2005
U.S. locations
2
States / cities
Athens, Ohio • Westerville, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 22, 2016 · Synced Oct 5, 2026, 4:11 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Prospective Survey of Menstrual Migraine & Prevention With Eletriptan

NCT00259649
View directory record Official record
Conditions
Migraine
Interventions
eletriptan
Drug
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
71 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2004
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 4, 2011 · Synced Oct 5, 2026, 4:11 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Bioequivalency Study of Naratriptan Hydrochloride 2.5 mg Under Fasted Conditions

NCT01161667
View directory record Official record
Conditions
Migraine
Interventions
naratriptan hydrochloride
Drug
Lead sponsor
Roxane Laboratories
Industry
Eligibility
18 Years to 45 Years
Enrollment
35 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007
U.S. locations
1
States / cities
Tacoma, Washington
Source: ClinicalTrials.gov public record
Updated Jan 23, 2018 · Synced Oct 5, 2026, 4:11 AM EDT
Active, not recruiting Not applicable Interventional

Treatment for Migraine and Mood

NCT05576467
View directory record Official record
Conditions
Migraine, Depressive Symptoms
Interventions
MBCT-Telephone, MBCT-Video, Enhanced Usual Care (EUC)
Behavioral
Lead sponsor
Amanda Shallcross
Other
Eligibility
18 Years and older
Enrollment
145 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
3
States / cities
The Bronx, New York • Winston-Salem, North Carolina • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 20, 2026 · Synced Oct 5, 2026, 4:11 AM EDT
Completed Not applicable Interventional

Mechanical Diagnosis and Therapy vs Traditional Physical Therapy in the Treatment of Mechanical Headaches

NCT03142945
View directory record Official record
Conditions
Headaches, Tension
Interventions
Traditional Physical Therapy, MDT based physical therapy
Other
Lead sponsor
Grand Valley State University
Other
Eligibility
18 Years to 65 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
1
States / cities
Grand Rapids, Michigan
Source: ClinicalTrials.gov public record
Updated Aug 2, 2018 · Synced Oct 5, 2026, 4:11 AM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy in Adult Subjects With Acute Migraines

NCT03237845
View directory record Official record
Conditions
Migraine, With or Without Aura
Interventions
Rimegepant, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
1,499 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
50
States / cities
Mobile, Alabama • Glendale, Arizona • Rogers, Arkansas + 44 more
Source: ClinicalTrials.gov public record
Updated Feb 16, 2023 · Synced Oct 5, 2026, 4:11 AM EDT
Terminated Phase 4 Interventional Results available

Prochlorperazine Versus Acetaminophen, Aspirin, and Caffeine for the Treatment of Acute Migraine

NCT01629329
View directory record Official record
Conditions
Migraine Headaches
Interventions
Aspirin, Acetaminophen, Caffeine pills, Prochlorperazine 10mg
Drug
Lead sponsor
Albert Einstein Healthcare Network
Other
Eligibility
18 Years to 65 Years
Enrollment
93 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 18, 2020 · Synced Oct 5, 2026, 4:11 AM EDT
Enrolling by invitation Not applicable Interventional

App-based Breathing Program for Migraine Relief

NCT07297901
View directory record Official record
Conditions
Migraine, Heart Rate Variability (HRV), Autonomic Nervous System, Headache (Migraine), Headache, Chronic Pain, mHealth, Breathing
Interventions
Baseline Survey, Heart rate variability biofeedback, Sham Control Group
Behavioral
Lead sponsor
Arizona State University
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Jul 23, 2026 · Synced Oct 5, 2026, 4:11 AM EDT
Terminated Phase 4 Interventional Results available

Therapy for Migraine Prevention in Children 6-11 Years of Age

NCT04050293
View directory record Official record
Conditions
Migraine Disorders, Headache Disorders
Interventions
SPN-538, Placebo
Drug
Lead sponsor
Supernus Pharmaceuticals, Inc.
Industry
Eligibility
6 Years to 11 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Jan 22, 2026 · Synced Oct 5, 2026, 4:11 AM EDT